<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2466">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981380</url>
  </required_header>
  <id_info>
    <org_study_id>AAAS2808</org_study_id>
    <secondary_id>R01AG058969</secondary_id>
    <nct_id>NCT03981380</nct_id>
  </id_info>
  <brief_title>11C-PIB PET Study in MESA at Columbia University</brief_title>
  <official_title>11C-PIB PET Study in the Multi Ethnic Study of Atherosclerosis at Columbia University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>José A. Luchsinger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct a study of brain positron emission tomography (PET) using&#xD;
      11C-PIB for the imaging of brain amyloid in 250 participants in the Multiethnic study of&#xD;
      atherosclerosis (MESA) at Columbia University Irving Medical Center in New York City.&#xD;
      Participants will be imaged only once with Pittsburgh Compound B (PIB) PET.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center PET study of 11C-PIB. Eligible participants are current participants&#xD;
      in the MESA study in New York City, without contraindications to MRI or PET procedures. Those&#xD;
      eligible will have one brain PET scan with 11C-PIB within 12 months of a brain MRI. Vital&#xD;
      signs will be checked prior to injection of 11C-PIB, 10 minutes after the injection, and&#xD;
      again at the completion of the PET scan. The primary outcome measure for amyloid will be&#xD;
      whole brain 11C-PIB SUVR. The relation between exposure groups and amyloid in the brain will&#xD;
      be analyzed using linear regression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Whole Brain 11C-PIB SUVR</measure>
    <time_frame>40 to 90 minutes post injection</time_frame>
    <description>Standardized uptake value ratio (SUVR) of 11C-PIB;The extent of Aβ deposition in the brain will be quantified by[11C]PiB uptake visualized by PET using standardized uptake volume ratio (SUVR) of 6 primary cortical areas (i.e., anterior cingulate, prefrontal cortex, lateral temporal cortex, posterior parietal cortex, precuneus cortex, and anteroventral striatum) relative to the uptake in the cerebellum</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Cognitive Impairment</condition>
  <condition>Vascular Diseases</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>MESA study participants</arm_group_label>
    <description>Current participants in the MESA study in New York City, 60 years or older, fluent in English or Spanish, able to participate in the brain imaging study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>11C-PIB</intervention_name>
    <description>Participants will be injected with an intravenous bolus of up to 5-15mCi (370 MBq) (+/-10%) of [11C]PiB (over 5-10 seconds).</description>
    <arm_group_label>MESA study participants</arm_group_label>
    <other_name>PIB</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      We will store plasma and serum.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Current participants in MESA study in New York City&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current participants in MESA study at Columbia University&#xD;
&#xD;
          -  60 years or older&#xD;
&#xD;
          -  Fluent in English and/or Spanish.&#xD;
&#xD;
          -  Able to participate in all scheduled evaluations and to complete all required tests&#xD;
             and procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active treatment for cancer&#xD;
&#xD;
          -  Any serious medical condition which would prevent long-term participation&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Weight &gt;300 pounds&#xD;
&#xD;
          -  Participants previously diagnosed or adjudicated to have dementia&#xD;
&#xD;
          -  Participants unwilling to undergo cognitive testing&#xD;
&#xD;
          -  Plans to leave the community within five years&#xD;
&#xD;
          -  Language barrier (speaks other than English, Spanish, Chinese)&#xD;
&#xD;
          -  Inability to give informed consent or to obtain consent from a Legally Authorized&#xD;
             Representative (LAR)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Luchsinger, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Medicine and Epidemiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>February 2, 2022</last_update_submitted>
  <last_update_submitted_qc>February 2, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>José A. Luchsinger</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Alzheimer Disease</keyword>
  <keyword>Cognitive Impairment</keyword>
  <keyword>11C-PiB</keyword>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Individual participant data (IPD) may be shared at the end of data collection with a mechanism supported by the National Institute on Aging</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

